-
Pfizer: Tender offer for King completed
NEW YORK — Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.
Pfizer said 230.7 million shares valued at $14.25 each were tendered, representing about 92.5% of King.
Pfizer made its $3.6 billion offer for King in October 2010. The offer cleared the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on Friday.
-
Pfizer one step closer to completing King acquisition
NEW YORK — Pfizer has cleared one of the main legal hurdles in its effort to purchase drug maker King Pharmaceuticals, Pfizer said Friday.
Pfizer, the world’s largest drug company, said the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had been terminated, one of the conditions necessary for the completion of Pfizer’s tender offer for King.
Pfizer announced plans in October to purchase Bristol, Tenn.-based King for $3.6 billion, or $14.25 per share.